Recent articles
Why Dynavax Technologies Corporation Stock Cratered in 2019
Can Dynavax's stock rebound after a dreadful 2019?
Why Pfizer Stock Fell 10.2% in 2019
The drugmaker's planned metamorphosis failed to impress investors, but that wasn't its only headwind.
2 Best Cannabis Stocks to Own in 2020
Canopy Growth and Cronos Group are in a class of their own among legal pot plays.
Why Biogen Stock Slumped Last Year
Biogen's decision to forgo a major deal weighed on its shares in 2019.
Why AbbVie Stock Dipped in 2019
AbbVie's shares had an off year in 2019. Here's why.
Better Buy: Biogen vs. Gilead Sciences
Which of these two biotech giants is the better buy in 2020?
Is HEXO Stock a Buy?
The Canadian cannabis grower and distributor had a dreadful 2019 that sent its shares tumbling to levels that could be tempting for bargain hunters.
Can Sarepta Therapeutics Stock Beat the Broader Markets in 2020?
Wall Street has high hopes for this mid-cap biotech in the coming year.
2 Pot Stocks to Flat Out Avoid in 2020
Aurora Cannabis and HEXO could be in serious trouble.
2 Biotech Stocks Poised to Soar in 2020
Acadia Pharmaceuticals and Axsome Therapeutics are top buyout candidates heading into the new year.
2 Must-Own Dividend Growth Stocks in 2020
AbbVie and Gilead Sciences are two outstanding dividend growth plays for 2020. Here's why.
Why Minerva Neurosciences Stock Is Cratering Today
Minerva's shares are crumbling today on the heels of a major clinical setback.
Why Clovis Oncology Stock Is Sinking Today
Clovis' $250 million mixed shelf offering isn't sitting well with shareholders today.
Why Axsome Therapeutics Stock Is On Fire Today
Axsome's clinical pipeline has scored yet another win.
Why Amarin Stock Is Jumping Today
Vascepa is now in position to become a blockbuster medication.
Why Sarepta Therapeutics Stock Is Jumping Today
Sarepta scored a surprise regulatory win yesterday.
Here's Why You Should Own Amgen Stock in 2020
The biotech titan is poised for another strong year in 2020.
Where Will Aurora Cannabis Be in 10 Years?
Like all pot stocks, Aurora is going through a rough patch at the moment. Should long-term investors take advantage of this downturn to build a position?
2 Top Biotech Buyout Candidates
Amarin and Aurinia will probably be bought out before the end of 2020. Here's why.
Better Buy: OrganiGram Holdings vs. Aphria
Which of these two Canadian pot stocks offers the better long-term opportunity for investors?